Drug Profile

NVX 508

Alternative Names: NVX-508

Latest Information Update: 28 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NuvOx Pharma
Class Antianaemics
Mechanism of Action Oxygen carriers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Vaso-occlusive crisis
New Molecular Entity No

Highest Development Phases

No development reported Vaso-occlusive crisis

Most Recent Events

28 Jul 2022 No recent reports of development identified for preclinical development in Vaso-occlusive-crisis in USA
02 Jul 2020 NVX 508 is still in preclinical development for Vaso-occlusive-crisis in sickle cell disease in USA (NuvOx Pharma pipeline, July 2020)
16 Jul 2018 NuvOx and the University of Pittsburgh withdraws a phase I trial in Vaso-occlusive crisis related to sickle cell anaemia in USA, prior to enrolment (NCT03013426)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com